You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Name1,10-Phenanthroline
Accession NumberDB02365  (EXPT02592)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIW4X6ZO7939
CAS number66-71-7
WeightAverage: 180.2053
Monoisotopic: 180.068748266
Chemical FormulaC12H8N2
InChI KeyInChIKey=DGEZNRSVGBDHLK-UHFFFAOYSA-N
InChI
InChI=1S/C12H8N2/c1-3-9-5-6-10-4-2-8-14-12(10)11(9)13-7-1/h1-8H
IUPAC Name
1,10-phenanthroline
SMILES
C1=CC2=CC=C3C=CC=NC3=C2N=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenanthrolines. These are aromatic polycyclic compounds containing the phenanthroline skeleton, which is a derivative of phenanthrene, and consists of two pyridine rings non-linearly joined by a benzene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPhenanthrolines
Sub ClassNot Available
Direct ParentPhenanthrolines
Alternative Parents
Substituents
  • 1,10-phenanthroline
  • Quinoline
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9879
Blood Brain Barrier+0.9825
Caco-2 permeable-0.5136
P-glycoprotein substrateNon-substrate0.6487
P-glycoprotein inhibitor INon-inhibitor0.8831
P-glycoprotein inhibitor IINon-inhibitor0.9805
Renal organic cation transporterNon-inhibitor0.7775
CYP450 2C9 substrateNon-substrate0.866
CYP450 2D6 substrateNon-substrate0.8486
CYP450 3A4 substrateNon-substrate0.7961
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6111
Ames testAMES toxic0.8512
CarcinogenicityNon-carcinogens0.9476
BiodegradationNot ready biodegradable0.9838
Rat acute toxicity2.1323 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9681
hERG inhibition (predictor II)Non-inhibitor0.8708
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point117 °CPhysProp
boiling point> 300 °CPhysProp
water solubility2690 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.78HANSCH,C ET AL. (1995)
pKa4.27 (at 20 °C)ALBERT,A ET AL. (1948)
Predicted Properties
PropertyValueSource
Water Solubility0.132 mg/mLALOGPS
logP2.31ALOGPS
logP2.29ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area25.78 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity53.9 m3·mol-1ChemAxon
Polarizability19.26 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-1900000000-e3edab983e41e183110aView in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Judith N. Burstyn, Omar Green, Bhavesh A. Gandhi, “BISCOPPER COMPLEXES, METHODS OF SYNTHESIS, AND USES THEROF.” U.S. Patent US20080206890, issued August 28, 2008.

US20080206890
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with 1,10-Phenanthroline.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with 1,10-Phenanthroline.
Acebutolol1,10-Phenanthroline may increase the bradycardic activities of Acebutolol.
AcetylcholineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Acetylcholine.
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with 1,10-Phenanthroline.
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with 1,10-Phenanthroline.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with 1,10-Phenanthroline.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with 1,10-Phenanthroline.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with 1,10-Phenanthroline.
Alprenolol1,10-Phenanthroline may increase the bradycardic activities of Alprenolol.
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with 1,10-Phenanthroline.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with 1,10-Phenanthroline.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with 1,10-Phenanthroline.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with 1,10-Phenanthroline.
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with 1,10-Phenanthroline.
ArecolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Arecoline.
Arotinolol1,10-Phenanthroline may increase the bradycardic activities of Arotinolol.
Atenolol1,10-Phenanthroline may increase the bradycardic activities of Atenolol.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with 1,10-Phenanthroline.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with 1,10-Phenanthroline.
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with 1,10-Phenanthroline.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with 1,10-Phenanthroline.
Befunolol1,10-Phenanthroline may increase the bradycardic activities of Befunolol.
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with 1,10-Phenanthroline.
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with 1,10-Phenanthroline.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with 1,10-Phenanthroline.
Betaxolol1,10-Phenanthroline may increase the bradycardic activities of Betaxolol.
BethanecholThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Bethanechol.
Bevantolol1,10-Phenanthroline may increase the bradycardic activities of Bevantolol.
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with 1,10-Phenanthroline.
Bisoprolol1,10-Phenanthroline may increase the bradycardic activities of Bisoprolol.
BoceprevirThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Boceprevir.
Bopindolol1,10-Phenanthroline may increase the bradycardic activities of Bopindolol.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with 1,10-Phenanthroline.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with 1,10-Phenanthroline.
Bufuralol1,10-Phenanthroline may increase the bradycardic activities of Bufuralol.
Bupranolol1,10-Phenanthroline may increase the bradycardic activities of Bupranolol.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with 1,10-Phenanthroline.
CarbacholThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Carbachol.
CarbamazepineThe metabolism of 1,10-Phenanthroline can be increased when combined with Carbamazepine.
Carteolol1,10-Phenanthroline may increase the bradycardic activities of Carteolol.
Carvedilol1,10-Phenanthroline may increase the bradycardic activities of Carvedilol.
Celiprolol1,10-Phenanthroline may increase the bradycardic activities of Celiprolol.
CevimelineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cevimeline.
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with 1,10-Phenanthroline.
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with 1,10-Phenanthroline.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with 1,10-Phenanthroline.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 1,10-Phenanthroline.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with 1,10-Phenanthroline.
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with 1,10-Phenanthroline.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with 1,10-Phenanthroline.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with 1,10-Phenanthroline.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with 1,10-Phenanthroline.
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with 1,10-Phenanthroline.
CyclophosphamideThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with 1,10-Phenanthroline.
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with 1,10-Phenanthroline.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with 1,10-Phenanthroline.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with 1,10-Phenanthroline.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with 1,10-Phenanthroline.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with 1,10-Phenanthroline.
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with 1,10-Phenanthroline.
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with 1,10-Phenanthroline.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with 1,10-Phenanthroline.
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with 1,10-Phenanthroline.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with 1,10-Phenanthroline.
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with 1,10-Phenanthroline.
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with 1,10-Phenanthroline.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with 1,10-Phenanthroline.
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with 1,10-Phenanthroline.
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with 1,10-Phenanthroline.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with 1,10-Phenanthroline.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with 1,10-Phenanthroline.
DipyridamoleThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Dipyridamole.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with 1,10-Phenanthroline.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with 1,10-Phenanthroline.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with 1,10-Phenanthroline.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with 1,10-Phenanthroline.
EPIBATIDINEThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with EPIBATIDINE.
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with 1,10-Phenanthroline.
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with 1,10-Phenanthroline.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with 1,10-Phenanthroline.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with 1,10-Phenanthroline.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with 1,10-Phenanthroline.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with 1,10-Phenanthroline.
Esmolol1,10-Phenanthroline may increase the bradycardic activities of Esmolol.
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with 1,10-Phenanthroline.
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with 1,10-Phenanthroline.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with 1,10-Phenanthroline.
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with 1,10-Phenanthroline.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with 1,10-Phenanthroline.
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with 1,10-Phenanthroline.
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with 1,10-Phenanthroline.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with 1,10-Phenanthroline.
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with 1,10-Phenanthroline.
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with 1,10-Phenanthroline.
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with 1,10-Phenanthroline.
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with 1,10-Phenanthroline.
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with 1,10-Phenanthroline.
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with 1,10-Phenanthroline.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with 1,10-Phenanthroline.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with 1,10-Phenanthroline.
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with 1,10-Phenanthroline.
GarlicThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Garlic.
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with 1,10-Phenanthroline.
GTS-21The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with GTS-21.
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with 1,10-Phenanthroline.
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with 1,10-Phenanthroline.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with 1,10-Phenanthroline.
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with 1,10-Phenanthroline.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with 1,10-Phenanthroline.
Indenolol1,10-Phenanthroline may increase the bradycardic activities of Indenolol.
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with 1,10-Phenanthroline.
Labetalol1,10-Phenanthroline may increase the bradycardic activities of Labetalol.
LobelineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Lobeline.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with 1,10-Phenanthroline.
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with 1,10-Phenanthroline.
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with 1,10-Phenanthroline.
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with 1,10-Phenanthroline.
MethacholineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Methacholine.
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with 1,10-Phenanthroline.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with 1,10-Phenanthroline.
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with 1,10-Phenanthroline.
Metoprolol1,10-Phenanthroline may increase the bradycardic activities of Metoprolol.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with 1,10-Phenanthroline.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with 1,10-Phenanthroline.
Mivacurium1,10-Phenanthroline may decrease the neuromuscular blocking activities of Mivacurium.
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with 1,10-Phenanthroline.
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with 1,10-Phenanthroline.
Nadolol1,10-Phenanthroline may increase the bradycardic activities of Nadolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with 1,10-Phenanthroline.
NicotineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Nicotine bitartrate.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with 1,10-Phenanthroline.
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with 1,10-Phenanthroline.
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with 1,10-Phenanthroline.
Oxprenolol1,10-Phenanthroline may increase the bradycardic activities of Oxprenolol.
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with 1,10-Phenanthroline.
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with 1,10-Phenanthroline.
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with 1,10-Phenanthroline.
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with 1,10-Phenanthroline.
Penbutolol1,10-Phenanthroline may increase the bradycardic activities of Penbutolol.
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with 1,10-Phenanthroline.
PethidineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Pethidine.
PilocarpineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Pilocarpine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with 1,10-Phenanthroline.
Pindolol1,10-Phenanthroline may increase the bradycardic activities of Pindolol.
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with 1,10-Phenanthroline.
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with 1,10-Phenanthroline.
Practolol1,10-Phenanthroline may increase the bradycardic activities of Practolol.
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with 1,10-Phenanthroline.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with 1,10-Phenanthroline.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with 1,10-Phenanthroline.
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with 1,10-Phenanthroline.
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with 1,10-Phenanthroline.
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with 1,10-Phenanthroline.
Propranolol1,10-Phenanthroline may increase the bradycardic activities of Propranolol.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with 1,10-Phenanthroline.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with 1,10-Phenanthroline.
Rapacuronium1,10-Phenanthroline may decrease the neuromuscular blocking activities of Rapacuronium.
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with 1,10-Phenanthroline.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with 1,10-Phenanthroline.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with 1,10-Phenanthroline.
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with 1,10-Phenanthroline.
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with 1,10-Phenanthroline.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with 1,10-Phenanthroline.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with 1,10-Phenanthroline.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with 1,10-Phenanthroline.
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with 1,10-Phenanthroline.
Sotalol1,10-Phenanthroline may increase the bradycardic activities of Sotalol.
St. John's WortThe metabolism of 1,10-Phenanthroline can be increased when combined with St. John's Wort.
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with 1,10-Phenanthroline.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with 1,10-Phenanthroline.
TemsirolimusThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Temsirolimus.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with 1,10-Phenanthroline.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with 1,10-Phenanthroline.
Timolol1,10-Phenanthroline may increase the bradycardic activities of Timolol.
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with 1,10-Phenanthroline.
TipranavirThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Tipranavir.
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with 1,10-Phenanthroline.
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with 1,10-Phenanthroline.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with 1,10-Phenanthroline.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with 1,10-Phenanthroline.
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with 1,10-Phenanthroline.
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with 1,10-Phenanthroline.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with 1,10-Phenanthroline.
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with 1,10-Phenanthroline.
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with 1,10-Phenanthroline.
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with 1,10-Phenanthroline.
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with 1,10-Phenanthroline.
VareniclineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Varenicline.
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with 1,10-Phenanthroline.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with 1,10-Phenanthroline.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)
Pharmacological action
unknown
General Function:
Transmembrane signaling receptor activity
Specific Function:
Receptor for the attractant L-aspartate and related amino and dicarboxylic acids. Tar mediates taxis away from the repellents cobalt and nickel. Unlike in E.coli tar, it does not mediates maltose taxis.Chemotactic-signal transducers respond to changes in the concentration of attractants and repellents in the environment, transduce a signal from the outside to the inside of the cell, and facilit...
Gene Name:
tar
Uniprot ID:
P02941
Molecular Weight:
59613.55 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Pseudomonas maltophilia
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Has a high activity against imipenem.
Gene Name:
Not Available
Uniprot ID:
P52700
Molecular Weight:
30800.635 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23